UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/14.01.26 | Real-time BOERSE MUENCHEN 11:41:24 2024-07-02 EDT | ||
| 5.33 EUR | +3.90% |
|
| Current month | -1.16% | ||
| 1 month | +8.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 5.33 | +3.90% |
| 24-07-01 | 5.13 | -1.16% |
| 24-06-28 | 5.19 | -2.63% |
| 24-06-27 | 5.33 | 0.00% |
| 24-06-26 | 5.33 | +2.70% |
Real-time BOERSE MUENCHEN
Last update July 02, 2024 at 11:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD2FED |
| ISIN | DE000HD2FED8 |
| Date issued | 2024-02-05 |
| Strike | 550 $ |
| Maturity | 2026-01-14 (561 Days) |
| Parity | 10 : 1 |
| Emission price | 4.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.08 € |
|---|---|
| Lowest since issue | 2.54 € |
| Spread | 0.04 € |
| Spread % | 0.77% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
471.2
USD
Average target price
468.3
USD
Spread / Average Target
-0.63%
- Stock Market
- Warrants
- Warrant
